pendent risk factors for cognitive impairment after stroke: ApoE 4 (OR = 3.7; 95% CI = 1.2-11.6), IQCODE score 6 3.44 (OR = 9.2; 95% = CI 2.3-37.2), total or partial anterior stroke syndromes (OR = 3.2; 95% CI = 1.3-8.0), and NIHSS total score 1 5 (OR = 7.3; 95% CI = 2.7-19.7). No association between ApoE 4 and pre-stroke cognitive reduction (IQCODE) was found. Conclusions: The presence of one or two ApoE 4 alleles may be a significant independent risk factor for cognitive impairment in the early phase after stroke.
The understanding of risk factors contributing to cognitive impairment after a stroke is still not complete. Whereas stroke type and severity, location of lesion, prestroke cognitive impairment, vascular factors (including previous strokes), age, and education are shown to be significantly related to post-stroke cognitive impairment, genetic factors are less studied. The apolipoprotein E 4 (ApoE 4) allele stands out as a particularly interesting candidate because it is a robust risk factor for late-onset Alzheimer's disease [9] . It is further associated with reduced cognitive functioning in non-demented elderly [10] , functional and cognitive outcomes after a traumatic brain injury, and functional outcomes after a haemorrhagic stroke and subarachnoid haemorrhage [11] . The role of the ApoE 4 allele in vascular dementia is uncertain [12] and few studies have examined the effect of the ApoE 4 allele on cognitive functioning in the early phase after a stroke. The results have been contradictory, possibly due to sampling characteristics and the cognitive tests being used [13] [14] [15] . We have examined, in a sample of stroke rehabilitation patients, the hypothesis that subjects with one or two ApoE 4 alleles have a higher prevalence of post-stroke cognitive impairment.
Subjects and Methods
Subjects diagnosed with ischaemic or haemorrhagic stroke from the Stroke Rehabilitation Unit at Ullevaal University Hospital between March 2005 and August 2006 were included. They were recruited consecutively, except in those periods when the researchers were off duty due to courses, conferences or holidays. Exclusion criteria were non-fluency in the Norwegian language, severe visual or hearing impairment, a history of serious psychiatric illness (defined as being hospitalized or treated for any psychiatric disorder according to the medical record in the hospital, by patient's self-report, or proxy information), and alcohol or drug abuse.
Post-Stroke Cognitive Functioning
Post-stroke cognitive functioning was measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) form A [16] , and the Mini Mental State Examination (MMSE) [17] . RBANS gives a total score on general cognitive functioning and index scores on cognitive functioning in five specific domains: immediate memory, visuospatial/constructional function, language, attention, and delayed memory. Subjects were scored with error on tasks they were incapable of performing (e.g. due to aphasia). Patients with hemiplegia that affected their dominant hand used the non-dominant hand for tests requiring writing/drawing skills. For subjects aged 65 years and above, RBANS index scores were calculated on the basis of ageand education-corrected norms for the geriatric population [18] . Original RBANS norms were applied for subjects below the age of 65 years. Individuals with a total index score 1 77.5, i.e. better than 1.5 SD below the mean, were considered cognitively intact, and those with a total index score ^ 77.5 as cognitively impaired. This cut-off point is in accordance with the Mayo Clinic's recommendations for mild cognitive impairment [19] .
Proposed Risk Factors for Post-Stroke Cognitive Impairment
The following potential risk factors for post-stroke cognitive impairment were examined: demographics (age, education, sex), pre-stroke vascular risk factors [hypertension (treated), hyperlipidaemia (treated), diabetes mellitus (treated), angina pectoris (treated), atrial fibrillation, previous myocardial infarction, previous stroke, previous transient ischaemic attack, and cigarette smoking], ApoE genotype, pre-stroke cognitive reduction, and stroke characteristics (type, location, and neurological severity).
Demographic and historical medical data (including prestroke vascular risk factors) were collected from medical records and interviews with patients and the patients' next of kin.
ApoE genotyping was performed using the following method: blood samples were immediately frozen and later analysed. Genomic DNA was extracted from peripheral white blood cells by MagNApure LC (Roche, Switzerland), according to the manufacturer's instructions. Primers were designed by the Primer3 program (http://primer3.sourceforge.net/) spanning the polymorphic site in the first part of exon 4 in the ApoE gene (RefSeq DNA NM_000041). Primer sequences are available on request.
The 576-bp products were purified by ExoSAP-IT and sequenced on an ABI 3730 DNA Analyzer using Big Dye Terminator v.3.1 sequencing kit from Applied Biosystems.
Haplotypes for ApoE isoforms 2, 3 and 4 were determined from base c.388 in codon 130 (T/C) and c.526 in codon 176 (T/C) (ref. sequence: NCBI36: 19: 50100279: 50105089: 1), which correspond to codon 112 and 158 in the earlier literature [20] .
The laboratory personnel were blinded to the results from the neuropsychological examination, while data collection and scoring of the cognitive data were undertaken by examiners blinded to the results from the ApoE genotyping.
Pre-stroke cognitive reduction was assessed by the 26-item Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) [21] with a higher average score indicating more severe impairment. The IQCODE measure was collected retrospectively through interviews with informants.
Neurological stroke-related impairments were examined by means of the National Institutes of Health Stroke Scale (NIHSS) [22] , comprising 14 items with a sum score ranging from 0 to 35 points, with a higher score indicating more severe neurological impairment. Both examiners (L.F. and J.W.) underwent video training before commencing the data collection.
Topographical location and the severity of the lesions were classified according to the Oxfordshire Community Stroke Project classification, subdividing strokes into four types based on symptoms and signs: total anterior circulation syndrome, partial anterior circulation syndrome, lacunar syndrome, and posterior circulation syndrome.
Clinical Assessment
Pre-stroke and post-stroke personal ADL functioning was assessed by the Barthel Index (BI) [23] , with a maximum score of 20 indicating independence. The Frenchay Activities Index (FAI) was used to measure pre-stroke instrumental ADL functioning [24] . It consists of 15 items, with a total score ranging from 15 to 527 60 (highest activity). The modified Rankin Scale (mRS) [25] , ranging from 0 (no symptoms) to 5 (severe disability), was used to measure the global degree of handicap. Post-stroke depressive symptoms were examined by the Montgomery-Asberg Depression Rating Scale (MADRS) [26] , consisting of 10 items adding up to a total score varying from 0 (no depressive symptoms) to 60 points. Pre-stroke BI and FAI measures were collected retrospectively through interviews with informants. Post-stroke BI measures were obtained through interviews with nurses in the stroke rehabilitation unit, while post-stroke mRS and MADRS were scored by two of the authors (J.W. and L.F.) on the basis of clinical evaluation and an interview with the patient.
Ethical and Legal Considerations
Oral and written informed consent was obtained from all the subjects. The study protocol was approved by the Regional Committee for Ethics in Medical Research and the Privacy Ombudsman.
Statistical Analyses SPSS version 14.0 was used. We examined the data for differences between the cognitively intact group and the impaired group with respect to demographic and clinical characteristics. Independent-samples t tests were used for normally distributed continuous variables, Mann-Whitney U tests were used for ordinal and non-normally distributed continuous variables, and 2 or Fisher's exact tests were used for categorical variables, with p ! 0.05 (two-sided) as the indicator of statistical significance. Significant variables were analysed further in a multiple logistic regression analysis. Logistic regression analysis was chosen because of the skewed distribution of data both in the dependent and the independent variables. When appropriate due to their distribution, ordinal explanatory variables were dichotomized according to recommended cut-off points in the logistic regression analysis. For the IQCODE, a cut-off score of 3.44 was applied according to Jorm [21] , while for the NIHSS we used a cut-off score of 5, which has been recommended as the criterion for individual patients to be discharged home versus discharged to a rehabilitation or nursing facility [27] . Next, we calculated the frequency of different ApoE alleles and analysed the data for differences in cognitive scores (IQCODE and RBANS total index, respectively) using Pearson 2 tests. Finally, we divided the subjects into two groups, ApoE 4-and ApoE 4+, and examined the demographic and clinical differences between them.
Results
Of 194 screened patients, 152 were included. Reasons for dropout were missing ApoE 4 genotyping (n = 34) or lack of co-operation for proper cognitive testing (n = 8). The excluded subjects did not differ significantly from those included with regard to any demographic variables, pre-stroke cognitive reduction, post-stroke neurological impairment, or stroke characteristics. Sociodemographic data and clinical background characteristics of the included subjects are shown in table 1 . The mean time between hospitalization and examination was 18.3 days (SD 13.4).
Due to lack of informants or subjects unwilling to involve an informant, only 131 informant interviews were obtained. No significant differences were found between subjects with and without an informant interview for any demographic variables, post-stroke cognitive functions, or prevalence of the ApoE 4 allele.
Risk Factors for Cognitive Impairment
The mean RBANS total index score was 74.5 (SD 13.8) and 92 patients (61%) were classified as cognitively impaired according to RBANS. Twenty-three (17.6%) persons had a score 6 3.44 on IQCODE, a score commonly regarded as indicative of cognitive decline [21] , in this case ahead of the stroke. Only 9 of them belonged to the group that had suffered a stroke earlier. Age was the only variable significantly associated with pre-stroke cognitive decline (p = 0.002). Table 2 shows the association between proposed risk factors and post-stroke cognitive impairment.
Both a univariate and a multivariate logistic regression analysis were carried out with cognitive impairment (as assessed by RBANS) as the dependent variable and the four significant variables from table 2 as independent variables (ApoE 4, IQCODE score 6 3.44, total or partial anterior stroke syndromes, and NIHSS total score 1 5). Table 3 shows the unadjusted and adjusted regression models, demonstrating that all these variables were significant and independent risk factors for post-stroke cognitive impairment. We also carried out a similar analysis with IQCODE and NIHSS total score entered as continuous variables. The results were essentially the same (data not shown). An extra univariate logistic regression analysis of the relation between ApoE 4 and post-stroke cognitive impairment was carried out, but this time excluding all subjects with pre-stroke cognitive reduction (IQCODE 6 3.44) and a previous stroke. The association was still strong and significant (OR = 6.4, 95% CI = 1.7-24.4, p = 0.006). (18) 13 (22) 42 (46) 12 (13) 17 (19) 24 (26) 0 (32) 10 (17) 12 (20) 8 (13) 15 (16) 21 (23) 17 (19) 32 (35) 20 (22) 1 
ApoE and Relation to Pre-Stroke and Post-Stroke Cognitive Functioning
As the ApoE genotype was a highly significant marker of post-stroke cognitive impairment ( table 3 ), the relationship between cognition and ApoE genotype was analysed further. Table 4 shows the distribution of different ApoE genotypes and the relation to overall cognitive functioning before the present stroke as measured by IQ-CODE and after the stroke as measured by the RBANS total index score. There was a statistically significant relationship between ApoE alleles and RBANS (after stroke), but not between ApoE alleles and IQCODE (before stroke). Analysing the relationships with RBANS and IQCODE regarded as ordinal (Kruskal-Wallis test) gave in principle the same results (data not shown).
The association between ApoE 4 and pre-stroke cognitive reduction was analysed more closely, this time only including subjects who had suffered a previous stroke. Although pre-stroke cognitive reduction (IQCODE score 6 3.44) was more frequent in previous stroke sufferers with the ApoE 4 allele compared to those without the ApoE 4 allele, the difference was not significant (44 vs. 19%, p = 0.192).
Further, we analysed the effect of having at least 1 4 allele on specific cognitive functions. Table 5 shows the various RBANS index scores for the ApoE 4-negative and ApoE 4-positive patients. In addition, we carried out independent-samples t tests to examine which RBANS subtests would best discriminate between the ApoE 4-positives and ApoE 4-negatives. List Recall (p = 0.012) and Story Recall (p = 0.008) were the only subtests that differed significantly between the two groups. We found no differences related to motor function in the dominant hand, aphasia, or MMSE score. No association was found between the ApoE 4 allele and post-stroke BI score, mRS score, MADRS score, duration of hospital stay, risk of dying in hospital, or risk of being discharged to an institution.
Discussion
Our results suggest that the ApoE 4 allele represents a genetic vulnerability constituting a significant and independent risk factor for cognitive impairment in the early phase after a stroke. Other risk factors were the location of the lesion (total or partial anterior stroke), the severity of neurological impairment, and pre-stroke cognitive reduction. Neither age nor years of education were associated with post-stroke cognitive impairment, which contradicts several previous studies. A possible explanation is that we have applied age-and education-adjusted norms in the scoring of the cognitive raw data. Regarding the index scores of RBANS, significant differences between ApoE 4 -positives and ApoE 4 -negatives were found for immediate memory, language, delayed memory and total index, while attention and visuospatial/constructional abilities were not significantly affected. With respect to the delayed memory index, it is interesting to note that only two of the four subtests, List Recall and Story Recall, showed significant differences, while the remaining two, List Recognition and Figure Recall , did not. In sum, the RBANS results suggest that tasks related to verbal learning/recall and language are especially prone to the effects of the ApoE 4 allele.
The ApoE 4 effect was found to be restricted to cognition only, as no association was found between the ApoE 4 allele and post-stroke ADL functioning, neurological impairment, or depressive symptoms. The lack of association with ADL functioning and neurological impairment is in accordance with the results from previous studies on ischaemic stroke patients [28] , but diverges from studies on haemorrhagic strokes where it has been suggested that carriers of the 4 allele might have a poorer outcome [29] . We found no such effect of stroke type, but this may be due to limited statistical power.
The effect of the ApoE 4 allele on cognition was dosedependent, as homozygote subjects performed worse than heterozygotes, who in turn performed worse than non-4 carriers ( table 4 ). All ApoE 4 homozygote subjects fell into the cognitive impairment group, but the number of such individuals was low.
Few studies have examined the effect of the ApoE 4 allele on cognitive functioning in the early phase after a stroke, and the results diverge [13] [14] [15] . The choice of neuropsychological methods and study samples could possibly explain the differences. Rowan et al. [13] examined patients aged 75 and over 3 months after a stroke with the Cambridge Assessment for Mental Disorders in the Elderly section B and the Cognitive Drug Research computerized battery, and found no association between ApoE 4 and cognition. They excluded patients with dementia, aphasia, serious illnesses and disabilities, and, as the authors comment, their strict exclusion criteria could have reduced the probability of detecting a relation between the ApoE 4 allele and cognitive deficits. The same research group [15] carried out a similar study among stroke patients more than 75 years old with vascular cognitive impairment but no dementia (vascular CIND). The subjects were examined 3 and 15 months after the stroke. At baseline, the ApoE 4 carriers were 2.5 times more likely to have CIND, and the ApoE 4 carriers with CIND also showed a higher rate of cognitive decline over the study period. Although these patients were studied almost 2.5 months later than ours, their baseline findings seem to accord well with our results. In the study by Baum et al. [14] , ischaemic stroke patients were examined 3 months after the stroke with the MMSE. No association with the ApoE 4 allele was found. Although the MMSE is extensively applied, its validity as a screening instrument for post-stroke cognitive impairment is dubious [30, 31] . Several limitations have been noted, including insensitivity to amnesia and overall cognitive impairment [32] , right-sided lesions [33] , impairments in abstract reasoning, executive functioning and visuoperception/construction [30] . We also applied the MMSE as part of our cognitive test battery, and in line with the results in the study by Baum et al. [14] , no significant relation was found between the ApoE 4 allele and MMSE performance ( table 5 ) . This suggests that a more extensive neuropsychological test battery than MMSE should be preferred in studies of the present type.
An important question is to what extent our findings could reflect an already pre-existing cognitive impairment in the ApoE 4-positives. A higher rate of prestroke cognitive decline in carriers of the ApoE 4 allele could be expected, as an association between ApoE 4 and cognitive impairment has been reported not only in Alz heimer's disease, but also in elderly persons not suffering from dementia [10] . Although the ApoE 4-positives had a higher mean total IQCODE score than the ApoE 4-negatives, no significant difference was found, neither when IQCODE was analysed as a continuous variable nor as a dichotomous variable with a cut-off point of 3.44. Neither did we find any association between the ApoE 4 allele and any other relevant clinical variables, including age, previous stroke or other vascular risk factors. The results thereby indicate that the increased prevalence of post-stroke cognitive impairment in the ApoE 4-positives cannot merely be explained by a higher rate of pre-stroke cognitive impairment. However, caution in the interpretation is warranted, since to our knowledge the IQCODE has not been properly validated in a stroke rehabilitation population. In fact, poor accuracy was found when the IQCODE was used to detect CIND and dementia in non-aphasic patients 1 year after a stroke [34] .
The underlying neuropathology of ApoE 4 contributing to cognitive impairment in stroke remains to be fully understood. Findings in neuroimaging studies of both animals and humans support the view that the ApoE4 brain is particularly vulnerable to the ischaemic effects of an acute stroke [35] [36] [37] . Sheng et al. [37] found a larger infarct size and more severe hemiparesis in transgenic mice with human ApoE4 compared to those with ApoE3 after 60 min of middle cerebral artery occlusion. Liu et al. [35, 36] examined ischaemic stroke patients with MRI and MRI/MR angiography and reported a significantly increased lesion growth and a higher vulnerability to ischaemic tissue damage in the ApoE 4-positives during the first week after the stroke. It has further been proposed that the negative ApoE 4 effect in neurodegenerative disease and brain injury may reflect the same underlying mechanisms. These may include increased amyloid-␤ protein accumulation, cytoskeletal alterations, oxidative stress, and a diminished capacity for neuronal regeneration and repair [38] . A more pronounced hippocampal volume loss over time among non-demented elderly ApoE 4 carriers has been reported in longitudinal studies [39] , pointing to a neurodegenerative factor associated with ApoE 4, especially in its homozygote form. In support of these findings, we found an association between ApoE 4 and cognition especially for memory-related tasks, despite the sampling of a wide range of cognitive measures. Interpreted in this context, the present results are compatible with an ApoE 4-related neuronal process being exposed as a result of the vascular crisis. A further analysis, however, will have to await a longitudinal study.
What are the clinical implications of our findings? Although we found a significant effect of ApoE 4 on poststroke cognitive functioning, the effect was moderate and restricted to the cognitive domain only, indicating that the effect on short-term rehabilitation outcomes may be marginal. However, results from other studies suggest that carriers of the ApoE 4 allele might be at particular risk of further cognitive decline and possibly also of developing post-stroke dementia.
Although not the initial objective of the study, we found an interesting association between ApoE 4 and primary intracerebral haemorrhage or an ischaemic stroke with secondary haemorrhagic transformation. Previous studies have produced conflicting results but suggest that ApoE 4 carriers may be more susceptible to lobar haemorrhagic strokes caused by cerebral amyloid angiopathy, but probably not hypertension-related haemorrhages [40] . As cerebral amyloid angiopathy is also associated with older age and Alzheimer's disease, one could speculate that the higher frequency of post-stroke cognitive impairment in the ApoE 4 carriers in our population is explained by the higher frequency of haemorrhagic strokes. However, this was not confirmed in a multivariate logistic regression analysis with ApoE 4 as the dependent variable, and cognitive impairment and haemorrhagic strokes as independent variables, as both variables turned out to be significantly and independently associated with ApoE 4.
A methodological strength of the present study is the very limited use of exclusion criteria, which probably make our data representative of stroke rehabilitation patients. However, some limitations apply. Subsamples of the study group were of limited size, making the results prone to type I errors. There are also restrictions in our choice of neuropsychological screening battery. Although the RBANS may be a useful neuropsychological screening battery in the early evaluation of stroke patients [6] , its 5-factor cognitive structure has not been supported in a factor analysis among stroke rehabilitation patients. The factor analysis showed a 2-factor solution comprising visuospatial/memory and language/verbal memory [41] , suggesting that the RBANS should not be recommended as the only measure in the screening for cognitive deficits after stroke. Furthermore, the RBANS was scored making use of North American norms since no Norwegian norms exist. However, all subjects were scored according to the same criteria and a high degree of cultural and educational similarity between the norm groups and the Norwegian subjects would contribute to high content validity of the norms as applied. All subjects were ethnic Norwegians, restricting the results to this ethnic group.
